Commerzbank Aktiengesellschaft FI Purchases 2,152 Shares of Kenvue Inc. (NYSE:KVUE)

Commerzbank Aktiengesellschaft FI lifted its position in Kenvue Inc. (NYSE:KVUE) by 17.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,759 shares of the company’s stock after acquiring an additional 2,152 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Kenvue were worth $313,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Patten Group Inc. lifted its holdings in Kenvue by 6.6% during the 4th quarter. Patten Group Inc. now owns 46,553 shares of the company’s stock valued at $994,000 after buying an additional 2,870 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Kenvue by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock valued at $533,169,000 after buying an additional 561,570 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Kenvue by 143.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company’s stock valued at $1,023,000 after buying an additional 28,216 shares in the last quarter. Schechter Investment Advisors LLC lifted its holdings in Kenvue by 29.2% during the 4th quarter. Schechter Investment Advisors LLC now owns 30,146 shares of the company’s stock valued at $644,000 after buying an additional 6,809 shares in the last quarter. Finally, Winslow Asset Management Inc. lifted its holdings in Kenvue by 3.3% during the 4th quarter. Winslow Asset Management Inc. now owns 160,050 shares of the company’s stock valued at $3,417,000 after buying an additional 5,121 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on KVUE. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Canaccord Genuity Group lifted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Citigroup cut their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Finally, Piper Sandler raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $23.75.

Kenvue Stock Down 1.6 %

Shares of Kenvue stock opened at $23.05 on Thursday. The firm’s 50 day moving average price is $21.57 and its 200-day moving average price is $22.30. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a market cap of $44.04 billion, a P/E ratio of 43.48, a PEG ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.